Bibliografía
1. Stadtmauer, E. A., et al. (2020). CRISPR-engineered T cells in patients with refractory cancer. Science, 367(6481), eaba7365.
2. Li...
Bibliografía 1. Stadtmauer, E. A., et al. (2020). CRISPR-engineered T cells in patients with refractory cancer. Science, 367(6481), eaba7365. 2. Lim, W. A., & June, C. H. (2017). The principles of engineering immune cells to treat cancer. Cell, 168(4), 724-740. 3. Kantoff, P. W., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 363(5), 411-422.
Compartir